Sally Ward | |
---|---|
Born | Elizabeth Sally Ward |
Alma mater | University of Cambridge |
Awards | Royal Society Wolfson Research Merit Award (2018) |
Scientific career | |
Fields | Immunology Cancer Biology Antibody Engineering Antibody Therapeutics [1] |
Institutions | Texas A&M University University of Texas Southwestern Medical Center University of Cambridge University of Southampton |
Thesis | Molecular genetics of an insectidal delta-endotoxin from Bacillus thuringiensis var israelensis. (1985) |
Doctoral advisor | David J. Ellar |
Website | www |
Elizabeth Sally Ward FRS is a British scientist who is Director of Translational Immunology at the Centre for Cancer Immunology in the University of Southampton. [1] [2] She was elected Fellow of the Royal Society in 2022. [3]
Ward was an undergraduate student at the University of Cambridge, where she studied the Natural Sciences Tripos with a focus on biochemistry. She remained at Cambridge for her doctoral research, working under the supervision of David J. Ellar at Gonville and Caius College, Cambridge. [4] [5] [6] Her PhD research investigated the genetics of delta endotoxin from Bacillus thuringiensis israelensis. [7]
Ward remained at Cambridge as a junior research fellow, working in both Gonville and Caius College and Sidney Sussex College, Cambridge. [8]
In 1990, Ward moved to the United States. She joined the University of Texas Southwestern Medical Center, where she was a member of the founding team of the Centre for Immunology. She was awarded various named chairs in Texas, including the Paul and Betty Meek-FINA Professorship. In 1996, Ward identified the Fc receptor, a regulator of Immunoglobulin G levels. [9] She moved to the Texas A&M University Health Sciences University in 2014. [9] In 2018, Ward returned to the United Kingdom, joining the University of Southampton as Professor of Molecular Immunology and Director of Translational Immunology. [10] [11]
Ward works on antibody and protein engineering to treat autoimmune disease. [12] She makes use of in vivo studies to design novel anti-body therapies for the treatment of cancer. Her early identification of the Fc receptor has resulted in the development of FcRn antagonist technologies. [13] [14] Ward has licensed these Abdegs (antibodies that enhance IgG degradation) to the pharmaceutical industry, resulting in anti-body therapeutics. [9] [14] [15]
Ward has developed advanced microscopies and image analysis techniques. She has demonstrated single molecule spectroscopy is capable of imaging single protein molecules at exceptional resolution. She uses multi-colour imaging to interrogate the cell surfaces. Using these approaches, Ward visualised the biological pathways intracellular endoscopes to the plasma membrane (and vice versa). [12] She has also pioneered open access software packages for miroscopy analysis. [12]